Patient-reported outcomes from the phase III, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/ KEYNOTE-A18 Study of pembrolizumab plus concurrent chemoradiotherapy among patients with high-risk, locally advanced cervical cancer

被引：0

作者：

Randall, Leslie ^{[1
]}

Sukhin, Vladyslav ^{[2
]}

Colombo, Nicoletta ^{[3
,4
]}

Korach, Jacob ^{[5
]}

Matsumoto, Takashi ^{[6
]}

Lalondrelle, Susan ^{[7
]}

Vizkeleti, Julia ^{[8
]}

Samouelian, Vanessa ^{[9
]}

Salani, Ritu ^{[10
]}

Salman, Pamela ^{[11
]}

Nogueira-Rodrigues, Angelica ^{[12
]}

Ayhan, Ali ^{[13
]}

Frentzas, Sophia ^{[14
,15
]}

Cueva, Juan ^{[16
]}

Kim, Yong-Man ^{[17
]}

Petru, Edgar ^{[18
]}

Milla, Dency Pilar ^{[19
]}

Sehouli, Jalid ^{[20
]}

Saevets, Valeriya ^{[21
]}

Yamada, Karin ^{[22
]}

Li, Kan ^{[23
]}

Szamreta, Elizabeth ^{[22
]}

Nguyen, Allison Martin ^{[22
]}

Pignata, Sandro ^{[24
]}

Lorusso, Domenica ^{[25
]}

机构：

[1] Virginia Commonwealth Univ, Richmond, VA USA

[2] Grigoriev Inst Med Radiol & Oncol, Kharkiv, Ukraine

[3] Univ Milano Bicocca, Milan, Italy

[4] European Inst Oncol IRCCS, Milan, Italy

[5] Sheba Med Ctr, Tel Aviv, Israel

[6] Ehime Univ, Matsuyama, Ehime, Japan

[7] Royal Marsden, London, England

[8] Natl Inst Oncol, Ctr Radiotherapy, Budapest, Hungary

[9] Univ Montreal, Montreal, PQ, Canada

[10] Univ Calif Los Angeles, Los Angeles, CA USA

[11] Oncovida Canc Ctr, Santiago, Chile

[12] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil

[13] Baskent Univ, Turkish Soc Gynecol Oncol TRSGO, Ankara, Turkiye

[14] Monash Hlth, Melbourne, Vic, Australia

[15] Monash Univ, Melbourne, Vic, Australia

[16] Hosp Clin Univ Santiago Compostela, Dept Med Oncol, Santiago De Compostela, Spain

[17] Univ Ulsan, Asan Med Ctr, Seoul, South Korea

[18] Med Univ Graz, Graz, Austria

[19] Hosp Nacl Guillermo Almenara Irigoyen, Lima, Peru

[20] Charite Univ Med Berlin, Berlin, Germany

[21] Chelyabinsk Reg Clin Ctr Oncol & Nucl Med, Chelyabinsk, Russia

[22] Merck & Co Inc, Rahway, NJ 07065 USA

[23] Merck & Co Inc, N Wales, PA USA

[24] Inst Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy

[25] Univ Cattolica Sacro Cuore, Rome, Italy

来源：

GYNECOLOGIC ONCOLOGY | 2024年 / 190卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S9 / S9

页数：1

共 50 条

[1] Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study
Duska, Linda
Xiang, Yang
Hasegawa, Kosei
Scambia, Giovanni
Leiva, Manuel
Elias, Pier Anyelo
Acevedo, Alejandro
Vizkeleti, Julia
Juliana Gomes, Andrea
Contreras Mejia, Fernando
Reiss, Ari
Ayhan, Ali
Lee, Jung-Yun
Saevets, Valeriya
Zagouri, Flora
Li, Kan
Yamada, Karin
Toker, Sarper
Pignata, Sandro
Lorusso, Domenica
GYNECOLOGIC ONCOLOGY, 2024, 190 : S8 - S9
[2] Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: the randomized, double-blind, phase 3 ENGOT-Cx11/GOG-3047/KEYNOTE-A18 study
Lorusso, Domenica
Xiang, Yang
Hasegawa, Kosei
Scambia, Giovanni
Leiva, Manuel
Ramos-Elias, Pier
Acevedo, Alejandro
Vizkeleti, Julia
Gomes, Andrea
Mejia, Fernando Contreras
Reiss, Ari
Ayhan, Ali
Lee, Jung-Yun
Saevets, Valeriya
Zagouri, Flora
Li, Kan
Yamada, Karin
Toker, Sarper
Pignata, Sandro
Duska, Linda R.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A2 - A2
[3] Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-Cx11/GOG 3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in patients with high-risk locally advanced cervical cancer
Pignata, Sandro
Sukhin, Vladyslav
Colombo, Nicoletta
Korach, Jacob
Matsumoto, Takashi
Lalondrelle, Susan
Vizkeleti, Julia
Randall, Leslie
Samouelian, Vanessa
Salman, Pamela
Nogueira-Rodrigues, Angelica
Ayhan, Ali
Cueva, Juan F.
Kim, Yong Man
Petru, Edgar
Yamada, Karin
Li, Kan
Szamreta, Elizabeth
Nguyen, Allison Martin
Lorusso, Domenica
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A42 - A42
[4] Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, doubleblind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study
Lorusso, D.
Xiang, Y.
Hasegawa, K.
Scambia, G.
Galves, M. H. Leiva
Elias, P. Ramos
Acevedo, A.
Vizkeleti, J.
Gomes, A. J. P. D. S.
Mejia, F. Contreras
Reiss, A.
Ayhan, A.
Lee, J. Y.
Saevets, V.
Zagouri, F.
Li, K.
Yamada, K. Ussui
Toker, S.
Pignata, S.
Duska, L. R.
ANNALS OF ONCOLOGY, 2023, 34 : S1279 - S1280
[5] Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: Overall survival results from the randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study
Lorusso, D.
Xiang, Y.
Hasegawa, K.
Scambia, G.
Leiva Galvez, M. H.
Elias, P. Ramos
Acevedo, A.
Bednarikova, M.
Gomes, A. J. P. D. S.
Mejia, F. Contreras
Reiss, A.
Zagouri, F.
Lee, J-Y.
Saevets, V.
Ayhan, A.
Liu, P.
Yamada, K. U.
Puglisi, M.
Pignata, S.
Duska, L.
ANNALS OF ONCOLOGY, 2024, 35 : S544 - S544
[6] ENGOT-CX11/GOG 3047/KEYNOTE-A18: A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF PEMBROLIZUMAB WITH CHEMORADIOTHERAPY IN PATIENTS WITH HIGH-RISK LOCALLY ADVANCED CERVICAL CANCER
Lorusso, D.
Colombo, N.
Coleman, R.
Randall, L.
Duska, L.
Xiang, Y.
Hasegawa, K.
Nogueira-Rodrigues, A.
Cibula, D.
Mirza, M. Raza
You, B.
Oaknin, A.
Christiaens, M.
Taskiran, C.
Sehouli, J.
Korach, J.
Martin, C.
Keefe, S.
Puglisi, M.
Pignata, S.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A71 - A71
[7] ENGOT-CX11/GOG 3047/KEYNOTE-A18: PHASE 3 RANDOMIZED STUDY OF PEMBROLIZUMAB plus CHEMORADIOTHERAPY FOR HIGH-RISK LOCALLY ADVANCED CERVICAL CANCER
Lorusso, D.
Xiang, Y.
Colombo, N.
Coleman, R. L.
Randall, L. M.
Duska, L.
Hasegawa, K.
Nogueira-Rodrigues, A.
Cibula, D.
Mirza, M. R.
You, B.
Oaknin, A.
Christiaens, M.
Taskiran, C.
Sehouli, J.
Korach, J.
Marth, C.
Yamada, K.
Puglisi, M.
Pignata, S.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A19 - A20
[8] Pembrolizumab or Placebo With Chemoradiotherapy Followed by Pembrolizumab or Placebo for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): A Randomized, Double-Blind, Phase 3 Clinical Trial
Lorusso, Domenica
Xiang, Yang
Hasegawa, Kosei
Scambia, Giovanni
Leiva, Manuel
Ramos-Elias, Pier
Acevedo, Alejandro
Sukhin, Vladyslav
Cloven, Noelle
Gomes, Andrea J. Pereira de Santana
Mejia, Fernando Contreras
Reiss, Ari
Ayhan, Ali
Lee, Jung-Yun
Saevets, Valeriya
Zagouri, Flora
Gilbert, Lucy
Sehouli, Jalid
Tharavichitkul, Ekkasit
Lindemann, Kristina
Lazzari, Roberta
Chang, Chih-Long
Lampe, Rudolf
Zhu, Hong
Oaknin, Ana
Christiaens, Melissa
Polterauer, Stephan
Usami, Tomoka
Li, Kan
Yamada, Karin
Toker, Sarper
Keefe, Stephen M.
Pignata, Sandro
Duska, Linda R.
OBSTETRICAL & GYNECOLOGICAL SURVEY, 2024, 79 (09) : 523 - 524
[9] Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/ GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
Lorusso, Domenica
Xiang, Yang
Hasegawa, Kosei
Scambia, Giovanni
Leiva, Manuel
Ramos-Elias, Pier
Acevedo, Alejandro
Sukhin, Vladyslav
Cloven, Noelle
Gomes, Andrea J. Pereira de Santana
Mejia, Fernando Contreras
Reiss, Ari
Ayhan, Ali
Lee, Jung-Yun
Saevets, Valeriya
Zagouri, Flora
Gilbert, Lucy
Sehouli, Jalid
Tharavichitkul, Ekkasit
Lindemann, Kristina
Lazzari, Roberta
Chang, Chih-Long
Lampe, Rudolf
Zhu, Hong
Oaknin, Ana
Christiaens, Melissa
Polterauer, Stephan
Usami, Tomoka
Li, Kan
Yamada, Karin
Toker, Sarper
Keefe, Stephen M.
Pignata, Sandro
Duska, Linda R.
LANCET, 2024, 403 (10434): : 1341 - 1350
[10] ENGOT-cx11/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer
Lorusso, D.
Xiang, Y.
Colombo, N.
Coleman, R.
Randall, L.
Duska, L.
Hasegawa, K.
Nogueira-Rodrigues, A.
Cibula, D.
Mirza, M. R.
You, B.
Oaknin, A.
Christiaens, M.
Taskiran, C.
Sehouli, J.
Korach, J.
Marth, C.
Keefe, S.
Puglisi, M.
Pignata, S.
ANNALS OF ONCOLOGY, 2020, 31 : S1341 - S1342

← 1 2 3 4 5 →